VANCOUVER, British Columbia, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) ("Avricore" or the "Company") a leader in pharmacy-based point-of-care testing solutions, plans to offer its HealthTab™ system as a stand-alone service to improve COVID19 case reporting.
“Timely and accurate reporting is key to managing community outbreaks, but it can be a challenge for even the major laboratory networks as we’ve seen recently in the U.S.,” says Rodger Seccombe, Avricore Chief Technology Officer and Co-Founder of HealthTab™. “Our middleware will bring plug-and-play, real-time electronic case reporting into community pharmacies. With new Health Canada licensed point-of-care devices expected later this year, we anticipate pharmacists will take on a greater role in COVID19 testing and tracking.”
The Company offers a device agnostic point-of-care testing platform, including a web API, that allows data to flow with patient consent, directly from an analyzer to the health records and reporting systems being utilized in a particular region.
“As more point-of-care testing moves into pharmacies, HealthTab™ provides the opportunity to aggregate and report results in real-time to health authorities. It’s a highly scalable, flexible and affordable solution to improve key health data monitoring and reporting from within the community, not only for COVID-19 cases, but also for adverse drug reactions, liver toxicity, diabetes and chronic disease,” added Avricore CEO Hector Bremner.
About HealthTab™ + RASTR
HealthTab™ is a proven point-of-care screening system, designed to support pharmacists evolving role. The system empowers patients to be proactive about their health by directly measuring and monitoring key safety tests and biomarkers of chronic disease. The HealthTab™ test is simple, fast, lab-accurate, and requires just a few drops of blood from a finger stick. Results can be printed in-store or accessed securely online.
Typically, HealthTab™ utilizes the Piccolo Xpress, an Abaxis Global Diagnostics chemistry analyzer, however, the system is designed to interface with other devices and third-party applications.
As part of this direction for HealthTab™, the Company developed a revolutionary model for utilizing the system’s unique ability to offer real-time evaluations of treated populations and even real-world evaluation clinical trials.
The name for this approach is Rapid Access Safety Test Reporting, or RASTR Network, whereby the network of HealthTab™ systems feedback de-identified data through to electronic health records and data management systems via its API capabilities. This is the first platform of harmonized analyzers, with fully integrated data-flow, for blood chemistry results to be sent to consumers, their healthcare teams and sponsors; such as researchers, insurance providers and the life-science sector.
The significance of this approach to the market is the enhanced access to screening and early detection of disease, better data for physicians and pharmacists to support their patients, plus new opportunities to conduct research and ensure patient safety.